Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to -$20.4 million.

  • aTYR PHARMA's Cash from Investing Activities fell 21354.62% to -$20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.6 million, marking a year-over-year decrease of 16704.83%. This contributed to the annual value of $17.2 million for FY2024, which is 18562.13% up from last year.
  • Per aTYR PHARMA's latest filing, its Cash from Investing Activities stood at -$20.4 million for Q3 2025, which was down 21354.62% from $3.3 million recorded in Q2 2025.
  • aTYR PHARMA's Cash from Investing Activities' 5-year high stood at $20.6 million during Q3 2022, with a 5-year trough of -$49.3 million in Q4 2021.
  • Over the past 5 years, aTYR PHARMA's median Cash from Investing Activities value was -$1.4 million (recorded in 2024), while the average stood at -$3.6 million.
  • Per our database at Business Quant, aTYR PHARMA's Cash from Investing Activities plummeted by 164068.06% in 2021 and then surged by 79134.57% in 2023.
  • aTYR PHARMA's Cash from Investing Activities (Quarter) stood at -$49.3 million in 2021, then surged by 104.05% to $2.0 million in 2022, then skyrocketed by 791.35% to $17.8 million in 2023, then plummeted by 134.15% to -$6.1 million in 2024, then crashed by 234.87% to -$20.4 million in 2025.
  • Its last three reported values are -$20.4 million in Q3 2025, $3.3 million for Q2 2025, and -$4.4 million during Q1 2025.